10:27 AM
 | 
Mar 22, 2019
 |  BC Week In Review  |  Company News  |  Deals

argenx gets first milestone payment from AbbVie for immuno-oncology therapy

AbbVie started a Phase I trial of ABBV-151 to treat solid tumors, triggering a $30...

Read the full 54 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >